Erin K. Brenner is Chief Product Dev. Officer of Pear Therapeutics, Inc.. Currently has a direct ownership of 43,310 shares of PEAR, which is worth approximately $433. The most recent transaction as insider was on Jan 20, 2023, when has been sold 8,690 shares (Class A Common Stock) at a price of $1.13 per share, resulting in proceeds of $9,819. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 43.3K
0% 3M change
0% 12M change
Total Value Held $433

Erin K. Brenner Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 20 2023
SELL
Open market or private sale
$9,819 $1.13 p/Share
8,690 Reduced 16.71%
43,310 Class A Common Stock
Jan 14 2023
BUY
Exercise of conversion of derivative security
-
22,000 Added 29.73%
52,000 Common Stock
Dec 09 2022
BUY
Exercise of conversion of derivative security
$15,000 $1.0 p/Share
15,000 Added 33.33%
30,000 Common Stock
May 25 2022
BUY
Exercise of conversion of derivative security
$15,000 $1.0 p/Share
15,000 Added 50.0%
15,000 Common Stock
EKB

Erin K. Brenner

Chief Product Dev. Officer
Boston, MA

Track Institutional and Insider Activities on PEAR

Follow Pear Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PEAR shares.

Notify only if

Insider Trading

Get notified when an Pear Therapeutics, Inc. insider buys or sells PEAR shares.

Notify only if

News

Receive news related to Pear Therapeutics, Inc.

Track Activities on PEAR